The technology’s promise can sound like science fiction—it might help us adapt to a radically different climate, or grow ...
Wells Fargo analyst Yanan Zhu maintained a Buy rating on Editas Medicine (EDIT – Research Report) on October 4. The company’s ...
Buy Rating on Intellia Therapeutics Backed by Promising Phase 1 Study and Upcoming Data Presentation
Zhu covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Bluebird Bio, and Arcturus Therapeutics ... Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 ...
BS: So, gene editing, when Jennifer Doudna and their team ... biggest areas in this gene therapy and editing. And bluebird bio (BLUE), a company, about one-year back, they got approval for ...
That includes Bluebird Bio, which already has approval in Europe ... founder Emmanuelle Charpentier and Intellia co-founder Jennifer Doudna shared the 2020 Nobel Prize in Chemistry for their ...
Šikšnys was a CRISPR-Cas9 pioneer and his group developed forms of the technology independently and at the same time as the Nobel Prize winners Emmanuelle Charpentier and Jennifer Doudna ...
UCSB Arts & Lectures and the Cancer Foundation of Santa Barbara host the Nobel Prize–winning biochemist for a talk on CRISPR ...
Co-hosted by UC Santa Barbara Arts & Lectures and the Cancer Foundation of Santa Barbara, the talk will discuss CRISPR-Cas9 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback